Janssen Targets Combinations As Next Step For Newly Approved Darzalex
This article was originally published in Scrip
Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.
You may also be interested in...
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.